+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JENBURPH JENBURPH

Jenburkt Pharmaceuticals Share Price

₹1,033.95 -6.1 (-0.59%)

04 Sep, 2026 4:01 PM (IST)

Jenburkt Pharmaceuticals live price: ₹1,033.95. It opened at ₹1,023 vs previous close ₹1,040; intraday high/low: ₹1,057/₹1,023. The 50 & 200 DMA stand at ₹1,072.60/₹1,092.40.

Jenburkt Pharmaceuticals Performance

  • Today's Low
  • ₹1,023
  • Today's High
  • ₹1,057
  • 52 Week Low
  • ₹944
  • 52 Week High
  • ₹1,321
  • Open Price₹1,023
  • Previous Close₹1,040
  • Volume599
  • 50 DMA₹1,072.60
  • 100 DMA₹1,084.00
  • 200 DMA₹1,092.40

Jenburkt Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -11.02%
  • Over 3 Month -9.12%
  • Over 6 Month + 3.4%
  • Over 1 Year -11.1%

Smart Investing Starts Here Start SIP with Jenburkt Pharmaceuticals for Steady Growth!

Invest Now

Jenburkt Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.9
  • PEG Ratio
  • 11.5
  • Market Cap Cr
  • 456
  • P/B Ratio
  • 2.2
  • Average True Range
  • 30.6
  • EPS
  • 74.4
  • Dividend Yield
  • 2
  • MACD Signal
  • -12.3
  • RSI
  • 42.17
  • MFI
  • 33.95

Latest Stock News Updates

Jenburkt Pharmaceuticals Ltd - 524731 - Announcement under Regulation 30 (LODR)-Change in Directorate

Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027 to 31st March, 2032, Approved with requisite mejority by the shareholders at 41st AGM of the Company held today i.e. 04th September, 2026.

Jenburkt Pharmaceuticals Ltd - 524731 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Submission of consolidated Voting Results and Scrutinizer''s Report on all the Resolutions as set out in the Notice Convening the 41st AGM of the Company held on 04th September, 2026.

Jenburkt Pharmaceuticals Ltd - 524731 - Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday, 04Th September, 2026.

Proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.

Jenburkt Pharmaceuticals Financials

Jenburkt Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,033.95
-6.1 (-0.59%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,051.80
  • 50 Day
  • ₹1,072.60
  • 100 Day
  • ₹1,084.00
  • 200 Day
  • ₹1,092.40

Resistance and Support

1037.85 Pivot Speed
  • R3 1,087.70
  • R2 1,072.30
  • R1 1,053.40
  • S1 1,019.00
  • S2 1,003.60
  • S3 984.70

Jenburkt Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-06 Quarterly Results
2026-05-05 Audited Results, Final Dividend & A.G.M.
2026-02-03 Quarterly Results
2025-10-28 Quarterly Results
2025-08-12 Quarterly Results
Date Purpose Remarks
2026-08-28 FINAL Rs.20.70 per share(207%)Final Dividend
2025-07-11 FINAL Rs.18.00 per share(180%)Final Dividend
View Jenburkt Pharmaceuticals Dividend History Arrow

Jenburkt Pharmaceuticals Shareholding Pattern

53.27%
46.62%
0.12%

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals is in the business of manufacturing, producing, developing and marketing a wide range of branded Pharmaceuticals and health care products. View More
  • NSE Symbol
  • JENBURPH
  • BSE Symbol
  • 524731
  • ISIN
  • INE354A01013

Similar Stocks to Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals FAQs

Jenburkt Pharmaceuticals share price is ₹1,033 As on 06 September, 2026 | 15:44

The Market Cap of Jenburkt Pharmaceuticals is ₹456.3 Cr As on 06 September, 2026 | 15:44

The P/E ratio of Jenburkt Pharmaceuticals is 13.9 As on 06 September, 2026 | 15:44

The PB ratio of Jenburkt Pharmaceuticals is 2.2 As on 06 September, 2026 | 15:44

The 52 week High & Low of Jenburkt Pharmaceuticals is ₹1321/₹944 respectively As on 06 September, 2026 | 15:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23